Key result
Early evolocumab evaluated vs placebo for achieving strict LDL-C targets in NSTEMI.
RCT
Placebo-controlled
1:1 ratio
No
Answers are grounded in this paper and cite their sources.
secondary prevention E levated low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk of adverse ischemic outcomes in the early post-acute coronary syndrome (ACS) period. he EVACS trial (Evolocumab in Acute Coronary Syndrome; ClinicalTrials.gov, Unique identifier: NCT03515304) enrolled patients with non-ST-segment-elevation myocardial infarction and troponin I of 5ng/mL and randomly assigned them in a 1:1 ratio to a single dose of evolocumab SQ 420 mg or matching placebo within 24 hours of presentation. We present here the LDL-C, the primary, and other atherogenic lipid outcomes, and interpret them in the clinical context by reporting the proportion of patients in each group achieving LDL-C AHA/ACC (<70 mg/dL) and ESC (<55 mg/dL for very high risk) targets at hospital discharge and 30-day follow-up. All patients received high-intensity statins unless contraindicated and were treated in accordance with current ACS guidelines. An independent Data Safety and Monitoring Board monitored the progress of the study, which was approved by the Johns Hopkins Institutional Review Board. All participants gave informed consent.
No takes yet. Share an insight, caveat, or question.
Leucker et al. (2020) conducted an RCT in Non-ST-segment-elevation myocardial infarction (NSTEMI). Evolocumab vs. Matching placebo was evaluated on Low-density lipoprotein cholesterol (LDL-C). Evolocumab SQ within 24 hours vs placebo was evaluated in NSTEMI for achieving <70 and </dL LDL-C targets at discharge and 30 days (no numerical results reported in abstract).
Synapse has enriched 10 related papers. Consider them for comparative context: